Physician profile
Aditya Verma
NPI 1902803372
$8,230.06
in general payments reported to CMS, 2019-2025
38 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $1,454 · 2021: $1,427 · 2022: $1,351 · 2023: $1,492 · 2024: $807 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,107.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,392.83 | 2019-2024 | Perclose Proglide, Accent |
| Boston Scientific Corporation | $1,204.05 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Avvigo Guidance System, Axios |
| Janssen Pharmaceuticals, INC | $597.69 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $539.00 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $405.98 | 2021-2023 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $368.76 | 2019-2021 | |
| Amgen INC. | $323.62 | 2019-2025 | Repatha, Repatha |
| Abiomed | $316.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $316.55 | 2019-2023 | Farxiga, Lokelma |
| Novo Nordisk INC | $315.93 | 2023-2025 | Ozempic |
| Edwards Lifesciences Corporation | $252.97 | 2021-2025 | Sapien 3 Ultra Resilia |
| Cathworks, INC. | $219.77 | 2022 | |
| Medtronic, INC. | $201.00 | 2021-2025 | Micra, Reveal Linq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.46 | 2021-2024 | Jardiance |
| Chiesi USA, INC. | $174.67 | 2019-2025 | Kengreal |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $154.97 | 2023 | Eylea |
| Novartis Pharmaceuticals Corporation | $137.31 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.33 | 2024-2025 | |
| Philips North America LLC | $129.91 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $117.43 | 2021 | |
| Cvrx, INC. | $101.02 | 2025 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $94.75 | 2020-2021 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $66.50 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $63.49 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $62.47 | 2020 | |
| Scpharmaceuticals INC. | $51.91 | 2025 | |
| Pfizer INC. | $39.42 | 2022 | |
| Lilly USA, LLC | $35.63 | 2023-2024 | Mounjaro |
| Penumbra, INC. | $29.93 | 2022 | |
| Cardiovascular Systems INC. | $28.60 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $27.02 | 2021 | |
| Shockwave Medical, INC | $22.84 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $22.68 | 2021 | |
| Asahi Intecc USA, INC. | $21.73 | 2022 | |
| Allergan, INC. | $17.31 | 2020 | |
| Reflow Medical INC | $17.27 | 2025 | |
| Avinger INC. | $13.74 | 2021 | |
| Infobionic, INC | $12.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.